CRISPR Therapeutics AG
NASDAQ:CRSPBiotechnology
+$1.43 today
- Market cap
- $3.90B
- Beta
- 1.70
- P/E (TTM)
- -9.2
- EPS (TTM)
- -$5.92
Volume 3.97M
Average 1.70M
CRSP Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
CRISPR Therapeutics AGNASDAQ: CRSP
Revenue · Q3 FY2026 · quarter ended Sep 2026
Revenue growth accelerates
Q3 FY2026 revenue of $12.67M rose 1325.1% year over year, ahead of the -33.1% change in trailing-twelve-month revenue. Sequentially, it rose 24.4% from the prior quarter. Over 3 fiscal years it compounded at +100.4% a year.
Context
- Revenue increased in 1 of the last 3 fiscal years.
What to watch
Whether revenue reaches the consensus estimate from 15 analysts of $35.47M (+910.5%) for the fiscal year ending Dec 2026, a step up from the -90.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $12.67M+24.4% QoQ
- Last fiscal yearDec 2025
- $3.51M-90.0% YoY
- LTMSep 2026
- $25.17M-33.1% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 3.51M USD
- Year-over-year change
- -90.0%
- 4-year CAGR
- -75.1%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.51M | -90.0% |
| FY2024 | 2024-12-31 | 35M | -90.5% |
| FY2023 | 2023-12-31 | 370M | +84762.4% |
| FY2022 | 2022-12-31 | 436K | -100.0% |
| FY2021 | 2021-12-31 | 913.08M | — |
Revenue vs competitors
How CRSP compares with its peers on the latest reported figures
- CRSP's LTM Sep 2026 revenue of $25.17M is the lowest of the 7 companies compared; the peer median is $76.96M.
- Its year-over-year change of -33.1% is the 5th highest of 7, against a peer median of -1.9%.
- Over three fiscal years its annual growth of +100.4% compares with a peer median of +12.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $156.04M | +158.9% | +31.9% | |
| LTM Mar 2026 | $141.31M | -40.5% | -29.1% | |
| LTM Mar 2026 | $87.82M | -44.0% | +14.8% | |
| LTM Mar 2026 | $66.09M | +45.0% | +9.1% | |
| LTM Mar 2026 | $45.07M | -11.9% | +10.9% | |
| LTM Mar 2026 | $38.69M | +8.0% | +27.1% | |
| LTM Sep 2026 | $25.17M | -33.1% | +100.4% | |
| Peer median (excluding CRSP) | $76.96M | -1.9% | +12.9% | |
Competitors are the stored peer set for CRSP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 913.08M | 436K | 370M | 35M | 3.51M |
| Cost of Revenue | 101.18M | 110.25M | 130.25M | 110.25M | 232.96M |
| Gross Profit | 811.9M | (109.81M) | 239.75M | (75.25M) | (229.45M) |
| Gross Margin | 88.9% | -25186.7% | 64.8% | -215.0% | -6537.0% |
| Research & Development | 340.57M | 461.65M | 387.33M | 320.65M | 265.33M |
| Selling, General & Admin | 99.69M | 102.46M | 76.16M | 72.98M | 73.54M |
| Operating Expenses | 438.38M | 563.35M | 462.29M | 391.32M | 338.87M |
| Depreciation & Amortization | 17.95M | 24.17M | 19.84M | 19.26M | 19.48M |
| EBITDA | 397.48M | (626.33M) | (130.89M) | (343.41M) | (558.49M) |
| EBITDA Margin | 43.5% | -143653.2% | -35.4% | -981.2% | -15911.3% |
| Operating Income | 373.53M | (673.16M) | (222.54M) | (466.57M) | (568.32M) |
| Operating Margin | 40.9% | -154394.7% | -60.1% | -1333.0% | -16191.4% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 6M | 22.66M | 71.82M | 103.9M | (9.65M) |
| Income Before Tax | 379.53M | (650.5M) | (150.72M) | (362.67M) | (577.97M) |
| Pre-Tax Margin | 41.6% | -149197.2% | -40.7% | -1036.2% | -16466.2% |
| Income Tax Expense | 1.87M | (325K) | 2.89M | 3.59M | 3.63M |
| Net Income | 377.66M | (650.18M) | (153.61M) | (366.25M) | (581.6M) |
| Net Margin | 41.4% | -149122.7% | -41.5% | -1046.4% | -16569.8% |
| EPS (Basic) | 4.97 | (8.36) | (1.94) | (4.34) | (6.47) |
| EPS (Diluted) | 4.70 | (8.36) | (1.94) | (4.34) | (6.47) |
| Weighted Avg Shares | 75.95M | 77.75M | 79.22M | 84.36M | 89.93M |
| Weighted Avg Shares (Diluted) | 80.39M | 77.75M | 79.22M | 84.36M | 89.93M |
CRISPR Therapeutics AG
NASDAQ:CRSP
Intrinsic Alpha fair value
Locked
Current Price
$40.19
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.